You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
|
---|---|
Published in |
Journal of Translational Medicine, December 2012
|
DOI | 10.1186/1479-5876-10-246 |
Pubmed ID | |
Authors |
Thomas F Gajewski, April KS Salama, Donna Niedzwiecki, Jeffrey Johnson, Gerald Linette, Cynthia Bucher, Michelle A Blaskovich, Said M Sebti, Frank Haluska, the Cancer and Leukemia Group B |
Abstract |
Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit proliferation of melanoma cell lines, we undertook a study to assess the impact of a FTI in advanced melanoma. As farnesylated proteins are also important for T cell activation, measurement of effects on T cell function was also pursued. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Poland | 1 | 2% |
Unknown | 56 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 19% |
Student > Ph. D. Student | 9 | 16% |
Student > Master | 7 | 12% |
Student > Bachelor | 6 | 11% |
Student > Doctoral Student | 5 | 9% |
Other | 6 | 11% |
Unknown | 13 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 21% |
Biochemistry, Genetics and Molecular Biology | 11 | 19% |
Agricultural and Biological Sciences | 10 | 18% |
Chemistry | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 4 | 7% |
Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2012.
All research outputs
#17,673,866
of 22,689,790 outputs
Outputs from Journal of Translational Medicine
#2,728
of 3,963 outputs
Outputs of similar age
#208,496
of 278,728 outputs
Outputs of similar age from Journal of Translational Medicine
#52
of 85 outputs
Altmetric has tracked 22,689,790 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,963 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,728 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.